B io s ta t i s t i c s  &  S ta t i s t i ca l  P rog ramm ing  /  
No va r t i s  In s t i tu te s  fo r  B ioMed i ca l  Re sea r ch
LJN452
CL JN452X2202
A  doub le  b l ind ,  random ized  p lacebo  con t ro l led  c rossove r
mu l t ip le  dose  s tudy o f  LJN452  to  assess  sa fe ty ,
to le rab i l i ty  and  e f f icacy  in  pa t ien ts  w i th  pr ima ry  b i le  ac id  
d ia r rhea  (pBAD)
S ta t i s t i ca l  Ana l y s i s  P lan  (SAP )
Do cumen t  t ype :  SAP  Do cumen ta t ion  –N IBR  
Do cumen t  s ta tu s : F ina l
Re lease  da te : 14- Aug- 2016
Numbe r  o f  pages : 12Pe r sona l  Da ta
P rope r ty  o f  Nova r t is
Fo r  bus iness  use  on ly
May  no t  be  used ,  d ivu lged ,  pub l ished  o r  o the rw ise  d isc losed
w i thou t  the  consen t  o f  Nova r t is
No va r t i s Fo r  bus iness  use  on ly Page  2
SAP CLJN452X2202
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Fo r  bus iness  use  on ly Page  3
SAP CLJN452X2202
Tab le  o f  con ten ts
T a b l e  o f  c o n t e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
L i s t  o f  t a b l e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1 I n t r o d u c t i o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1 . 1 S c o p e  o f  d o c um e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1 . 2 S tudy r e f e r en c e  do cum en t a t ion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1 . 3 S tudy o b j e c t i v e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1 . 3 . 1 P r im a ry ob j e c t i v e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1 . 3 . 2 S e cond a ry o b j e c t i v e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1 . 4 S tudy d e s ign  and  t r e a tm en t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2 F i r s t  i n t e r p r e t a b l e  r e s u l t s  (F IR ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
3 I n t e r im  a n a l y se s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
4 S t a t i s t i c a l  m e t h o d s :  A n a l y s i s  s e t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
5 S t a t i s t i c a l  m e t h o d s  f o r  P h a rm a c o k i n e t i c  (PK )  p a r am e t e r s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8
5 . 1 V a r i a b l e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
5 . 2 D e s c r i p t i v e  a n a ly se s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
5 . 2 . 1 G r a p h i c a l  p r e s e n t a t i o n  o f  r e s u l t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
6 S t a t i s t i c a l  m e t h o d s  f o r  P h a rm a c o dy nam i c  (PD )  p a r am e t e r s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
6 . 1 P r im a ry ob j e c t iv e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
6 . 1 . 1 V a r i a b l e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
6 . 1 . 2 D e s c r i p t i v e  a n a ly se s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
6 . 1 . 3 S t a t i s t i c a l  m o d e l ,  a s s um p t i o n s  a n d  h yp o t h e s e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
7 S t a t i s t i c a l  m e t h o d s  f o r  s a f e ty  and  to l e r ab i l i ty  d a t a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0
7 . 1 P r im a ry ob j e c t iv e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0
7 . 1 . 1 V a r i a b l e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0
7 . 1 . 2 D e s c r i p t i v e  a n a ly se s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1
7 . 1 . 3 G r a p h i c a l  p r e s e n t a t i o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1
L is t  o f  tab les
F i g u r e  1- 1 S tudy d e s ign . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Co rpo ra te  Con f iden t ia l  In fo rma t ion
6Co rpo ra te  Con f iden t ia l  In fo rma t ionCo rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
[COMPANY_001] For business use only Page 4
SAP CLJN452X2202
Table 4-1 Protocol deviation codes and anal ysis sets.............................................. 7
No va r t i s Fo r  bus iness  use  on ly Page  5
SAP CLJN452X2202
1 In t roduc t ion  
1 .1 Scopeo f  documen t
T h e  RAP  do cum en t s  con t a in  d e t a i l e d  in fo rm a t ion  to  a i d  th e  p rodu c t ion  o f  S t a t i s t i c s  &  
P r o g r amm i n g  i n p u t  i n t o  t h e  C l i n i c a l  S t u d y R epo r t  (CSR )  fo r  t r i a l  CLJN452X2202 .
T h e  S t a t i s t i c a l  a n a l y si sp l a n  (SAP )  d e s c r i b e s  t h e  im p l em e n t a t i o n  o f  th e  s t a t i s t i c a l  an a ly s i s  
p l a n n e d  i n  t h e  p r o t o c o l .
1 .2 S tudy  re fe rence  documen ta t ion
Th i s  SAP  h a s  b e e n  d ev e lop ed  u s ing  C l i n i c a l  T r i a l  P r o t o c o l  v e r s i o n  v 0 2( i n c o r p o r a t i n g  
Am e n dm e n t  2 )  app rov ed  by  [CONTACT_3433] e  SRC  on  0 9A u g u s t2 0 1 6 .  
1 .3 S tudy  ob jec t ives
1 .3 .1 P r ima ry ob jec t ives
 T o  d e t e rm i n e  t h e  s a f e ty  a n d  t o l e r a b i l i t y  o f  L JN452  in  p a t i en t s  w i th  p r im a ry  b i l e  a c i d  
d i a r r h e a( pBAD )
 T o  a s s e s s  t h e  e f f e c t  o f  LJN 4 5 2  o n  c l i n i c a l  s y mp tom s  exp e r i en c ed  by p a t i en t s  w i th  
pBAD
1 .3 .2 Seconda ry ob jec t ives
 T o  as s e s s  t h e  p h a rm a c o k i n e t i c s  o f  L JN 4 5 2  i n  pBAD  p a t i e n t s

Co rpo ra te  Con f iden t ia l  In fo rma t ionT o  a s s e s s  t h e  e f f e c t  o f  LJN 4 5 2  o n  u s e  o f  r e s c u e  m e d i c a t i o n s  d u r i n g  t h e  s t u d y  p e r iod
[COMPANY_001] For business use only Page 6
SAP CLJN452X2202
1.4 Stud y design and treatment
This is a multi- center, double blind (patient and investigator blind, sponsor open label),
randomized placebo controlled, crossover study  to assess safety , tolerability  and efficacy  of
LJN452 in patients with pBA D. In this study  approximately  [ADDRESS_566143] 24 completers. 
This is a non- confirmatory trial.
Figure 1-1 Study  design
In treatment period 1 on Day 1 patients will receive either 60 μ g LJN452 or placebo orally
once daily for 14 days in a 1:1 ratio. Pharmacokinetic (PK), pharmacody namic (PD) and
safet y samples will be collected on Day [ADDRESS_566144] 7 days, up to a maximum of 28 days. At the end ofthewashout period, patients will 
return tothe study  site for period 2 of the study . Period 2 will be identical to period 1 except 
that the treatments will be crossed over.
The r andomization will be maintain ed at a 1:[ADDRESS_566145] interpretable results (FIR)
First interpretable results (FIR) will be provided for this trial.
The study  FIR template (mock slides) can be found in CREDI  in the study  RAP f older .
The template shows the analy sis/ results to be presented in the FI R. Study  outputs required to 
be created at the time of the FIR will be highlighted in TFL shells document and marked as 
“Key ” in the Programming Deliverables Tracker (PDT) output list. 
No va r t i s Fo r  bus iness  use  on ly Page  7
SAP CLJN452X2202
3  In te r im  ana lyses  
4 S ta t is t ica l  me thods :  Ana lysis  se ts
F o r  p a t i en t sfo r  wh i ch  t h e  a c t u a l  t r e a tm e n t  r e c e i v e d  do e s  no t  m a t ch  t h e  r andom i z ed  t r e a tm e n t  
t h e  t r e a tm e n t  a c t u a l l y  r e c e i v e d  w i l l  b e  u s e d  f o r  t h e  a n a l y si s .
F o r  p a t i en t s  f o r  wh i ch  t h e  a c t u a l  s equ en c e  o f  t r e a tm e n t s  r e c e i v e d  do e s  no t  m a t c h  t h e  
r a n d om i z e d  s e q u e n c e  o f  t r e a tm e n t s ,  t h e  a c t u a l  s equ en c e  w i l l  b e  u s ed  fo r  a n a l y si s  i n v o l v i n g  a  
s e q u e n c e  c om p o n e n t  ( e .g .  ANOVA s  w i th  a  s e q u e n c e  e f f e c t )  i f  t h e  a c tu a l  s e q u e n c e  i s  o n e  o f  
t h e  s e q u e n c e s  p l a n n e d  in  t h e  s tudy  d e s i g n .  I f  t h e  a c t u a l  s e q u e n c e  i s  n o t  o n e  o f  t h e  s equ en c e s  
p l a n n e d  in  t h e  s tudy  d e s i g n ,  t h e  r andom i z ed  s e q u e n c e  w i l l  b e  u s ed  f o r  an a ly s i s  i n v o l v i n g  a  
s e q u e n c e  c om p o n e n t  bu t  d a t a  po in t s  f rom  p e r iod s  in  w h i c h  t h e  p a t i en th a s  no t  r e c e i v e d  th e  
r a n d om i z e d  t r e a tm e n t  w i l l  b e  e x c l u d e d  f r om  t h e  a n a l y s i s .  
T h e  s a f e ty  a n a l y si s  s e t  w i l l  i n c l u d e  a l l  p a t i e n t s  t h a t  r e c e i v e d  a n y  s tudy  d rug .
Th e  PK  an a lys i s  s e t  w i l l  in c lud e  a l l  p a t i en t s  w i th  av a i l ab l e  PK  d a t a  and  no  p ro to co l  d ev i a t ion s  
w i t h  r e l e v a n t  im p a c t  o n  PK  d a t a .
Th e  PD  an a lys i s  s e t  w i l l  in c lud e  a l l  p a t i en t s  w i th  av a i l ab l e  PD  d a t a  and  no  p ro to co l  d ev i a t ion s
w i t h  r e l e v a n t  im p a c t  o n  PD  d a t a .
T h e  a n a ly si s  s e t s  a n d  p r o t o c o l  d e v i a t i o n  c o d e s  a r e  r e l a t e d  a s  f o l l ow s :
Tab le  4 -1  P ro toco l  dev ia t ion  codes  and  ana lys is  se ts
Ca tego ry
Dev ia t ion  codeTex t  desc r ip t ion  o f  dev ia t ion Da ta  exc lus ion
Pa t ien tsa re  exc luded  f rom  a l l  (sa fe ty )ana lys is  in  case  o f  these  
PDs :  Exc lude  pa t ien tcomp le te ly  
f rom  a l l  ana ly s is  se ts
I 0 1 IC F  n o t  o b ta i n e d Y e s
S01 Sub j e c t  d id  no t  r e c e iv e  any s tudy  d rugCo rpo ra te  Con f iden t ia l  In fo rma t ion
Ye s
[COMPANY_001] For business use only Page 8
SAP CLJN452X2202
Category
Deviation codeText description of deviation Data exclusion
Patients are excluded from PK analysis in case of these PDs: Exclude patient from PK 
analysis set 
S01 Subject did not receive any study drug Yes
I01 ICF not obtained Yes
Patients are exclu ded from PD analysis in case of these PDs: Exclude patient from PD 
analysis set
S01 Subject did not receive any study drugYes
   I01 ICF not obtained Yes
Patients are excluded from PK and PD analysis in case of these 
PDs:Exclude patient from PK an d 
PD analysis sets
S01 Subject did not receive any study drugYes
I01 ICF not obtained Yes
If updates to this table are needed, an amendment to the SAP needs to be implemented prior to
DBL .
5 Statistical methods for P harmacokinetic (PK) parameters
5.1 Variables 
The following and other appropriate pharmacokinetic parameters may be determined using 
the actual recorded sampling times and non-compartmental method(s) with Phoenix 
WinNonlin (Version 6.3 or higher): AUClast, AUCtau, Cmax, Cmin, Cav,ss, Tmax, CL/F, 
Racc (accumulation ratio = AUCtau, ss/AUCtau,day  1).
5.2 Descriptive analy ses
LJN452 concentration data will be listed by [CONTACT_69867]/sampling time point. Descriptive 
summary  statistics will be provided by  [CONTACT_765]/sampling time point .
Pharmacokinetic parameters will be calculated as described in Section 5.1 of the protocol and 
will be listed by [CONTACT_69867]. Summary  statistics will include mean (arithmetic and 
geometric), SD, CV (arithmetic and geometric), median, minimum and maximum. An 
exception tothis is Tmax where median, minimum and maximum will be presented. 
Concentrations below LLOQ will be treated as zero in summary  statistics and for PK 
parameter calculations. A geometric mean will not be reported if the dataset includes zero 
values.
No va r t i s Fo r  bus iness  use  on ly Page  9
SAP CLJN452X2202
5 .2 .1 G raph ica l  presen ta t ion  o f  resu l ts
A r i t hm e t i c  m e a n  (SD )  a n d  g e om e t r i c  m e a n  (95%  C I)  p l a sm a  c o n c e n t r a t i o n  d a t a  w i l l  b e  
p l o t t e d  a c r o s s  t im e .
Ov e r l ayi n g  i n d i v i d u a l  p l a sm a  c o n c e n t r a t i o n - t im e  p r o f i l e s  w i l l  b e  g e n e r a t e d .
I n d i v i d u a l  p l a sm a  c o n c e n t r a t i o n - t im e  p r o f i l e s  w i l l  b e  g e n e r a t e d .
6 S ta t is t ica l  me thods  fo r  Pha rmacodynam ic  (PD )  pa rame te rs
6 .1 P r ima ry ob jec t ive
T o  a s s e s s  t h e  e f f e c t  o f  LJN 4 5 2  o n  c l i n i c a l  s y mp tom s  exp e r i en c ed  by p a t i en t s  w i th  pBAD .
6 .1 .1 Va r iab les  
T h e  p r im a ry  a n a ly si s  v a r i a bl e s  a r e :  a )  s too l  f r equ en cy ,  b )  a n d  s too l  fo rm  a s s e s s e d  by  t h e  
B r i s t o l  s t o o l  c h a r t .
6 .1 .2 Desc r ip t ive  ana lyses
Summ a ry s t a t i s t i c s  ( i n c l u d i n g  m e d i a n  a n d  IQR )  o f  th e  s too l  f r equ en cya n d  a v e r a g es too l  fo rm
(w e e k l y  a n d  b iw e e k ly )  fo r  e a ch  t r e a tm en t  a s  w e l l  a st h e  d i ff e r e n c e  a n d  %  c h a n g e  b e tw e en  th e  
2  t r e a tm e n t sw i l l  b e  p r o v i d e d  by  v i s i t .B a s e l i n e  d a t a  w i l l  b e  s umm a r i z e d  by  t r e a tm e n t  and  
v i s i t .  T h e  n um b e r  a n d  p e r c e n t a g e  o f  p a t i en t sw i th  e a c h  s too l  f o rm  w i l l  b e  p r o v i d e d  b y  
t r e a tm e n t  a n d  v i s i t .  Th e  s too l  f r e q u e n c y  a n d  s t oo l  f o rm  d a t a  w i l l  b e  l i s t ed  by  t r e a tm en t  
s e q u e n c e ,  p a t i e n t  a n d  v i s i t .  
6 .1 .3 S ta t is t ica l  mode l ,  assump t ions  and  hypo theses
Ar e p e a t e d  m e a s u r e s  an a ly s i s  w i l l  b e  d o n e  f o r  th etw o - d im e n s i o n a l  e n d p o i n t :  w e e k l y s too l  
f r equ en cy  a nd  t h e  c o r r e s p o n d i n g  a v e r a g e  s too l  fo r m.  T h e  an a ly s i s  w i l l  i n c l u d e  f ix ed  e f f e c t s  
f o r  s e q u e n c e  (D r u g /P l a c e b o  o r  P l a c e b o /D r u g ) ,  T r e a tm e n t  ( W e e k  1  d r u g ,  W e e k  2  d r u g ,  W e e k  
1  p l a c eboo r  W e ek  2  P l a c e b o ) ,  a n d  p e r i o d  ( 1  o r  2 ) .T h e  mod e l  w i l l  a s sum e  an  a rb i t r a ry 2  by  2  
c o v a r i a n c e  m a t r ix  f o r  t h e  tw o - d ime n s i o n a lendpo in t  ( f r equ en cy ,  fo rm )  a n d  a  compound  
sy mm e t ry c o v a r i a n c e  m a t r ix  f o r  e a c h  ind iv idu a l  e n d  po in t .  Po in t  e s t im a t e s  o f  t h e  w e e k ly  &  
b iw e e k ly  t r e a tm en t  e f f e c t  on  s too l  f r equ en cy  and  t h e  c o r r e s p o n d i n g  av e r ag e  s too l  fo rm  w i l l  b e  
r e p o r t e d  t o g e t h e r  w i t h  9 5%  s im u l t a n e o u s  c o n f i d e n c e  i n t e r v a l s  ( c o n f i d e n c e  e l l i p s o i d s ) .
6 .1 .3 .1 Hand l ing  o f  m iss ing  va lues /censo r ing /d iscon t inua t ionsCo rpo ra te  Con f iden t ia l  In fo rma t ion
M i s s i n g  v a l u e s  w i l l  b e  a s s um e d  m i s s i n g  a t  r a n d om .  N o  im p u t a t i o n  o f  m i s s i n g  v a l u e s  w i l l  b e  
d o n e  f o r  a ny  a n a l y se s .
No va r t i s Fo r  bus iness  use  on ly Page  10
SAP CLJN452X2202
6 .1 .3 .2 G raph ica l  presen ta t ion  o f  resu l ts
B o x p l o t s  t o  v i s u a l i z e  t r e a tm e n t  d i f f e r e n c e s  i ns too l  f r equ en cy  a n d  s t o o l  f o rmw i l l  b e  c r e a t e d .
6 .1 .3 .3 Suppo r t ive  ana lys is
B a s e l i n e  w e e k ly  s too l  f r equ en cy  a nd  t h e  c o r r e s p o n d i n g  a v e r a g e  s too l  fo rm  w i l l  b e  a n a l y zed  
u s i n g  t h e  s am e  m e t h o d  a s  d e s c r i b e d  i n  S e c t ion  6 .1 .3t o  a s s e s s  u n e q u a l  c a r r y o v e r  e f f e c t s .
Th e  numb e r  and  p e r c en t ag e  o f  sub j e c t s  u s ing  lop e r am id e  w i l l  b e  t abu l a t ed  by t r e a tm en t .  To t a l  
w e e k ly  lop e r am id e  u s e  ( in  mg )  w i l l  b e  summ a r i z ed  by  t r e a tm en t  and  v i s i t( i n c l u d i n g  b a s e l i n e ) .  
T h e  s too l  ind ex ,  c a l cu l a t ed  a s  [w e ek ly  s too l  f r equ en cy *m e an  s too l  f o rm ]+ l o p e r am i d e  u s e  
[w e ek ly  m g * 3 ] ,  w i l l  a l s o  b e  s umm a r i z e d  a n d  an a ly z ed  u s ing  a  l i n e a r  m ix ed  e f f e c t s  mod e l  
i n c l u d i n g  s equ en c e ,  p e r iod  a n d  t r e a tm e n t  a s  f ix ed  e f f e c t s  a n d  sub j e c t  n e s t ed  w i th in  s equ en c e  
a s  a  r a n d ome f f e c t .
7 S ta t is t ica l  me thods  fo r  sa fe ty and  to le rab i l i ty  da ta
7 .1 P r ima ry ob jec t ive
T o  d e t e rm i n e  t h e  s a f e ty  a n d  t o l e r a b i l i t y  o f  L JN 4 5 2  i n  p a t i e n t s  w i t h  pBAD .
7 .1 .1 Va r iab les  Co rpo ra te  Con f iden t ia l  In fo rma t ion
A d v e r s e  e v e n t s ,  v i t a l  s i g n s  ( b l o o d  p r e s s u r e ,  pu l s e  r a t e ,  body  t em p e r a t u r e ) ,  ECG  in t e rv a l s ,  
l abo r a to ry  m e a su r em en t s ,  a s  w e l l  a s  p a t i e n td em o g r a p h i c s ,  b a s e l i n e  c h a r a c t e r i s t i c s ,  a n d  
t r e a tm e n t  i n f o rm a t i o n .
[COMPANY_001] For business use only Page 11
SAP CLJN452X2202
7.1.2 Descriptive analy ses
Patient demographics and other baseline characteristics
All data for background and demographic variables will be listed by [CONTACT_445148] . Summary  statistics will be provided for all patients, as well as for each treatment 
sequence.
Relevant medical history, current medical conditions, results of laboratory screens, drug tests 
and an y other relevant info rmation will be listed by  [CONTACT_445149] .
Treatment
Data for study  drug administration and concomitant therapi[INVESTIGATOR_445147] .
Vital signs
All vital signs data will be listed by [CONTACT_19016] , patient, and visit/time and if ranges 
are available abnormalities (and relevant orthostatic changes) will be flagged. Summary 
statistics will be provided by  [CONTACT_10659]/time.
ECG evaluations
All ECG data will be listed by [CONTACT_19016] , patient and visit/time, abnormalities will 
be flagged. Summary  statistics will be provided by [CONTACT_10659]/time.
Clinical laboratory  evaluations
All laboratory  data will be listed by [CONTACT_19016] , patient, and visit/time and if normal 
ranges are available abnormalities will be flagged. A separate listing is provided presenting all 
parameters in a patient with any abnormal values. Summary  statistics will be provided by 
[CONTACT_10659]/time. Baselines will be the last available measurement in each treatm ent 
period post washout and prior to dosing.
Log-transformed lipid (total Cholesterol, LDL, HDL, triglycerides) and LFT (GGT, ALP, 
AST, ALT)data will be analyzed using a mixed effects model including sequence, period, 
and treatment as fixed effects and su bject nested within sequence as a random effect.
Adverse events
All information obtained on adverse events will be display ed by [CONTACT_117912] .
The number and percentage of patients with adverse events will be tabulated by [CONTACT_50110] a breakdown by [CONTACT_3148]. An adverse event starting in one period 
and continuing into the next period is counted only in the onset period. A patient with 
multiple adverse events within a body  system and treatment period is only counted once 
towar ds the total of this body  system and treatment.
7.1.3 Graphical presentation 
Boxplots to visualize trends in longitudinal safet y data (lab parameter s) will be created.
No va r t i s Fo r  bus iness  use  on ly Page  12
SAP CLJN452X2202
Co rpo ra te  Con f iden t ia l  In fo rma t ion